Genaissance Pharmaceuticals, University of Utah, Yale, Hycor Biomedical, University of Louisville, Tm Bioscience, Lexicon Genetics, Decode Genetics | GenomeWeb

Genaissance Amends License Deal with University of Utah, Yale

Genaissance Pharmaceuticals has amended a license agreement with the University of Utah and Yale University relating to cardiac ion channel genes associated with sudden cardiac death syndromes, the company announced last week.

The amendment relates to more than 50 issued and pending patents Genaissance licensed in the United States and other countries that cover five cardiac ion channel genes associated with Long QT, Brugada, and related syndromes

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.